Department of Trauma Orthopedic and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Orthopedic, The Affiliated Minzu Hospital of Guangxi Medical University, Nanning, China.
Medicine (Baltimore). 2023 Jan 27;102(4):e32784. doi: 10.1097/MD.0000000000032784.
Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. This study assessed the course of research and development for denosumab in terms of publications over the past 2 decades. Web of Science databases were searched to identify publications related to research on denosumab from January 1, 2005 to December 31, 2022. The VOS Viewer software (version 1.6.17) and Bibliometrix package in R (version 4.1.3) were used in this study. There were 5119 denosumab-related publications during this period. The total number of citations of denosumab-related publications reached 94917. The most articles were published in the field of Endocrinology Metabolism. As an international language, English remains the most popular language for writing papers. Five of the top ten institutions originated in the USA. Through the VOS Viewer analysis, we found that the relationships between Amgen Inc. with its collaborations were grouped into 4 clusters, the USA was the mainland for research and development on denosumab, closely collaborating with many other countries, such as Canada, Japan, England, and China. Wagman RB from USA was the most prolific author with 119 publications. The journal with the most publications was Osteoporosis International (481 publications). The most cited article was "Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis" with 2053 citations. The clinical trial comprised 6 of the 10 most frequently cited publications, and the rest consisted of reviews. The most frequent keywords for publications since January 1, 2014 were "prevention" and "management," indicating that a number of prevention and management measures have been developed to regulate the use of denosumab in treating osteoporosis. Our research provided a comprehensive review of denosumab-related publications, suggesting that the development of denosumab is a long process and numerous clinical trials have been conducted before applications in clinical settings.
地舒单抗是一种针对核因子-κB 配体的人源单克隆抗体，能有效抑制骨吸收。文献计量学可以直观地展示某一主题的研究发展过程、研究现状、研究热点和发展趋势，为研究人员提供参考。本研究通过对过去 20 年有关地舒单抗的出版物进行评估，分析地舒单抗的研发历程。检索 2005 年 1 月 1 日至 2022 年 12 月 31 日 Web of Science 数据库中与地舒单抗研究相关的出版物。本研究采用 VOS Viewer 软件（版本 1.6.17）和 R 中的 Bibliometrix 包（版本 4.1.3）。在此期间，共检索到 5119 篇地舒单抗相关出版物，地舒单抗相关出版物的总被引频次达到 94917 次。发文量最多的领域是内分泌学和新陈代谢。英语作为国际语言，仍然是论文写作最流行的语言。排名前 10 的机构中有 5 家来自美国。通过 VosViewer 分析发现，安进公司（Amgen Inc.）与其合作机构之间的关系被分为 4 个聚类，美国是地舒单抗研发的大陆，与加拿大、日本、英国和中国等许多国家密切合作。来自美国的 Wagman RB 是最具影响力的作者，共发表了 119 篇文章。发文量最多的期刊是《骨质疏松国际》（Osteoporosis International），共发表了 481 篇文章。被引频次最高的文章是“地舒单抗用于治疗绝经后骨质疏松症患者的骨折预防”，被引频次为 2053 次。自 2014 年 1 月 1 日以来，出版物中出现频率最高的关键词是“预防”和“管理”，这表明已经制定了许多预防和管理措施来规范地舒单抗在治疗骨质疏松症中的应用。本研究对地舒单抗相关出版物进行了全面综述，表明地舒单抗的发展是一个漫长的过程，在应用于临床之前已经进行了大量的临床试验。
